Skip to main content

20-09-2016 | Endocrine cancers | Book chapter | Article

99. Chemotherapy for Anaplastic Thyroid Cancer

Authors: MD David A. Liebner, MD Sigurdis Haraldsdottir, MD Manisha H. Shah

Publisher: Springer New York


Anaplastic thyroid cancers (ATC) account for roughly 2.2 % of all thyroid cancers in the USA (Hossain et al. J Clin Oncol 28(15s):abstr 5588, 2010) and are believed to arise from differentiated thyroid cancers (DTC) via the accumulation of genetic abnormalities that result in dedifferentiation and an aggressive phenotype (Wiseman et al. J Clin Oncol 24(18s):abstr 5556, 2006). Unfortunately, ATC is usually advanced at the time of diagnosis, with approximately 76–79 % of all patients having disease extending beyond the thyroid/neck at the time of presentation (Hossain et al. J Clin Oncol 28(15s):abstr 5588, 2010; Chen et al. Am J Clin Oncol 31(5):460–4, 2008). In the vast majority of patients, surgery alone has been associated with poor outcomes, leading to investigation into additional therapeutic options.

Please log in to get access to this content

Related topics